- FDA granted full approval to Zymeworks’ zanidatamab for HER2-amplified biliary tract cancer on September 24, 2026, the company’s first U.S. regulatory approval.
- Peak U.S. sales in BTC are modelled at $1.2 billion USD (~$1.69B CAD), with Jazz Pharmaceuticals handling co-commercialization and de-risking launch costs.
- Health Canada’s Priority Review decision is expected in H1 2027, covering roughly 1,100 eligible Canadian patients diagnosed with biliary tract cancer annually.
- Despite the approval, ZYME dipped with a broader biotech selloff; the long-term re-rating thesis hinges on Phase 3 gastric data and path to free cash flow by 2028.
Vancouver-based Zymeworks Inc. (TSX: ZYME; NYSE: ZYME) received full FDA approval on September 24, 2026 for zanidatamab (brand name: Ziihera) as a second-line treatment for adults with HER2-amplified biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer. The approval marks the company’s first regulatory green light in the United States and a pivotal inflection point for a biotech that has traded largely on pipeline promise since its 2017 TSX listing.
The FDA’s decision was based on data from the Phase 2b HERIZON-BTC-01 trial, in which zanidatamab — a bispecific HER2-targeted antibody — delivered an objective response rate (ORR) of 41.3% in HER2-amplified BTC patients who had progressed on at least one prior line of gemcitabine-based chemotherapy. Median duration of response reached 12.5 months. The label covers an estimated 4,500 to 6,000 newly eligible U.S. patients per year, a population that has historically had no approved HER2-directed therapy.
Commercial Opportunity and Competitive Landscape
The global biliary tract cancer therapeutics market was valued at approximately $980 million USD in 2025 and is projected to exceed $2.1 billion USD by 2032, driven by expanding biomarker testing and new targeted approvals. Analysts at Canaccord Genuity and RBC Capital Markets have modelled zanidatamab’s peak U.S. sales in BTC at $1.2 billion USD annually — equivalent to roughly $1.69 billion CAD at the current USD/CAD rate of 1.4089 — assuming 40–45% market penetration within five years. Zymeworks has a co-commercialization agreement with Jazz Pharmaceuticals for the U.S. market, which limits Zymeworks’ net revenue capture but substantially de-risks launch costs.
Competition in HER2-positive BTC is sparse but emerging. Eli Lilly’s LY-HER2 program and a Daiichi Sankyo HER2-targeted ADC (DS-8201 in BTC) are in mid-stage trials. For now, zanidatamab has first-mover advantage in a segment where oncologists have had no approved HER2 option. Importantly, zanidatamab’s bispecific design — simultaneously binding HER2’s ECD2 and ECD4 domains — differentiates it mechanistically from trastuzumab biosimilars, supporting a premium pricing thesis in the range of $18,000–$22,000 USD per month of therapy.
Health Canada Pathway and Canadian Investor Angle
A parallel submission to Health Canada under the Priority Review pathway was filed in Q2 2026. A decision is anticipated in H1 2027. Canada sees approximately 1,100 new biliary tract cancer diagnoses annually, representing a smaller but clinically meaningful domestic opportunity. Canadian retail investors holding ZYME on the TSX should note that the stock trades in CAD and tracks the NYSE listing closely, with typical intraday spreads of 1–2 cents on moderate volume.
Stock Reaction and Long-Term Thesis
Despite the landmark approval, ZYME shares pulled back modestly in Thursday’s session, consistent with a broader biotech selloff — the XBI ETF fell 1.91% to $155.20, and the IBB declined 0.27% to $206.60. The “sell the news” dynamic is common post-approval as event-driven funds rotate out. The longer-term thesis, however, rests on three catalysts: a potential Health Canada approval in 2027, readout of the Phase 3 HERIZON-GEA-01 trial in HER2-positive gastroesophageal adenocarcinoma (a market more than four times the size of BTC), and royalty economics from Jazz’s U.S. commercialization effort that could turn Zymeworks free-cash-flow positive by fiscal 2028.
| Metric | Detail |
|---|---|
| Drug / Brand Name | Zanidatamab / Ziihera |
| Indication | 2L HER2-amplified biliary tract cancer |
| Regulatory Outcome | FDA Full Approval — September 24, 2026 |
| Eligible U.S. Patients (annual) | ~4,500–6,000 |
| Peak Sales Estimate (U.S., BTC) | ~$1.2B USD (~$1.69B CAD) |
| Health Canada Decision Expected | H1 2027 |
| U.S. Co-Commercialization Partner | Jazz Pharmaceuticals |
For long-term investors, the approval removes the binary regulatory risk that has historically suppressed ZYME’s valuation multiple. With a commercial-stage asset now on the U.S. market and a deeper pipeline in gastric and breast cancer indications, Zymeworks transitions from a speculative development-stage company to an emerging commercial biotech — a re-rating that typically takes two to four quarters to fully materialize in the stock price.
